Generic placeholder image

Applied Clinical Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2213-476X
ISSN (Online): 2213-4778

Managing and Responding to FDA Inspections

Author(s): Susan Margaret Muhr Leister

Volume 2, Issue 1, 2015

Page: [33 - 36] Pages: 4

DOI: 10.2174/2213476X02666150903203830

Price: $65

Abstract

Is your facility inspection ready at all times? Most organization are not ready at all times and, therefore find preparing for any type of FDA Inspection to be overwhelming. This paper provides guidance on how to prepare and how to respond to the FDA, specifically for larger clinical site inspections, Clinical Investigators, and drug manufacturer inspections. Also, tips are provided on how to take a proactive inspection readiness approach. These same inspection readiness strategies can be applied in a reduced manner by smaller organizations to help successfully manage regulatory inspections.

Keywords: Audits, bioresearch monitoring program (BIMO), FDA (Food and Drug Administration), inspection readiness, quality management systems, regulatory inspections.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy